Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $108.7 million.

  • Harmony Biosciences Holdings' Free Cash Flow rose 5413.63% to $108.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.9 million, marking a year-over-year increase of 3484.33%. This contributed to the annual value of $218.7 million for FY2024, which is 18.58% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Free Cash Flow stood at $108.7 million for Q3 2025, which was up 5413.63% from $79.3 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Free Cash Flow registered a high of $108.7 million during Q3 2025, and its lowest value of $12.5 million during Q1 2021.
  • In the last 5 years, Harmony Biosciences Holdings' Free Cash Flow had a median value of $37.5 million in 2021 and averaged $47.5 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 27357.42% in 2021, then tumbled by 2892.12% in 2022.
  • Harmony Biosciences Holdings' Free Cash Flow (Quarter) stood at $37.5 million in 2021, then dropped by 28.92% to $26.7 million in 2022, then surged by 186.97% to $76.6 million in 2023, then fell by 1.97% to $75.0 million in 2024, then skyrocketed by 44.79% to $108.7 million in 2025.
  • Its last three reported values are $108.7 million in Q3 2025, $79.3 million for Q2 2025, and $33.9 million during Q1 2025.